microRNAs in the Diagnosis of Atherosclerotic Plaque Instability

NCT ID: NCT05680935

Last Updated: 2025-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-05

Study Completion Date

2024-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It's a non-randomized, intervention, prospective, single-center study.

The aim of the work is to identify of biomarkers of unstable atherosclerosis in brachiocephalic arteries

Tasks:

* identify microRNAs, the expression of which is characteristic of unstable atherosclerotic lesions;
* to assess the relationship of miRNA and trimethylamine N-oxide with the progression of unstable atherosclerotic lesions;
* to determine the effect of the level of plasma trimethylamine N-oxide on the progression of atherosclerotic lesions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries and up to 30 people - the control group without brachiocephalic atherosclerosis.

As part of the standard of medical care, the patient has already undergone and received the results of the following examinations before being included in the study:

* general clinical laboratory tests (complete blood count, urinalysis, low density lipoproteins, very low density lipoproteins, high density lipoproteins, total cholesterol, triglycerides, total protein, alanine aminotransferase, aspartate aminotransferase, creatinine, urea, glucose)
* ultrasound and/or multislice computed tomography (MSCT) of brachiocephalic arteries.

Patients with clinically significant atherosclerosis of the brachiocephalic arteries were hospitalized for an operation - carotid endarterectomy with obtaining surgical material (atherosclerotic plaque with adjacent intima).

Specific methods of the planned study (procedures for examination and treatment of the patient):

1. In addition, all patients will take blood (20 ml) from the cubital vein to isolate microRNAs and determine the plasma content of trimethylamine N-oxide (TMAO). The resulting surgical material will be sent for histological examination and microRNA isolation.
2. The following statistical data processing methods will be used: frequency distribution, arithmetic mean, mode, median, standard deviation, determination of normal distribution, Student's t-test, Pearson's test, Fisher's test, Spearman's correlation coefficient, multiple linear regression.

During the operation according to the standard protocol of carotid endarterectomy, an atherosclerotic plaque with a small area of adjacent intima is removed. An atherosclerotic plaque obtained during a carotid endarterectomy will be sent for histological examination to determine signs of instability. The obtained data will be compared with the level of isolated microRNAs in blood and tissue (atherosclerotic plaque, intima) to detect microRNAs, which are determined during an unstable course of the atherosclerotic process.

The data obtained will make it possible to predict the unstable course of atherosclerosis using non-invasive studies. This will allow timely detection of unstable plaques and help to make a decision and determine the tactics of managing patients with borderline sizes of atherosclerotic lesions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis of Artery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

atherosclerosis of the brachiocephalic arteries

The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). The study will include up to 50 people - the study group with atherosclerosis of the brachiocephalic arteries.

Group Type EXPERIMENTAL

blood microRNA

Intervention Type DIAGNOSTIC_TEST

all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

plaque and intima microRNA

Intervention Type DIAGNOSTIC_TEST

The resulting surgical material will be sent for microRNA isolation.

histological examination of the plaque

Intervention Type DIAGNOSTIC_TEST

The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.

blood level trimethyl N-oxide

Intervention Type DIAGNOSTIC_TEST

all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

No brachiocephalic atherosclerosis

The recruitment of patients will be carried out at the University Clinical Hospital No. 1 of the Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Up to 30 people - the control group without brachiocephalic atherosclerosis.

Group Type EXPERIMENTAL

blood microRNA

Intervention Type DIAGNOSTIC_TEST

all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

blood level trimethyl N-oxide

Intervention Type DIAGNOSTIC_TEST

all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood microRNA

all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.

Intervention Type DIAGNOSTIC_TEST

plaque and intima microRNA

The resulting surgical material will be sent for microRNA isolation.

Intervention Type DIAGNOSTIC_TEST

histological examination of the plaque

The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.

Intervention Type DIAGNOSTIC_TEST

blood level trimethyl N-oxide

all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Availability of written informed consent to participate in research work;
2. Age from 18 to 85 years;
3. Availability of data from a general blood test, blood lipid profile (total cholesterol, very low density lipoproteins, low density lipoproteins, high density lipoproteins, triglycerides);
4. Absence of clinical signs of atherosclerosis of brachiocephalic arteries (no stroke, transient ischemic attack. On auscultation of the carotid arteries, there are no additional noises);
5. Absence of signs of atherosclerosis of the brachiocephalic arteries according to ultrasound duplex scanning (USDS) and/or multispiral computed tomography (MSCT) angiography of the brachiocephalic arteries;
6. Conducted outpatient visit at a research center with clinical and biochemical blood tests performed, ultrasound examination of arterial vessels and/or multispiral tomography of arterial vessels with contrast enhancement and/or hospitalization at a research center.


1. Chronic kidney disease stage 3b and above (glomerular filtration rate \< 45 ml / min / 1.73 sq.m);
2. The presence of severe somatic pathology (with the exception of atherosclerosis of the carotid arteries and conditions caused by it), reducing life expectancy to less than 6 months;
3. Chronic somatic diseases in the acute stage;
4. Weight less than 40kg and more than 125kg;
5. Pregnancy.

Exclusion Criteria

1\. Refusal to continue participation in the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

I.M. Sechenov First Moscow State Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anastasiia Lomonosova, no

Role: PRINCIPAL_INVESTIGATOR

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Moscow, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Related Links

Access external resources that provide additional context or updates about the study.

http://doi.org/10.18087/cardio.2019.2.10214

Multislice Computed Tomography Capabilities in Assessment of the Coronary Arteries Atherosclerotic Lesions.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

132578

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Atorvastatin on Myonecrosis
NCT00344019 TERMINATED PHASE4